Latest studies into retatruptide peptide demonstrate notable outlook for treating obesity and type 2 disease. The peptide, a dual activator of GLP-1 and glucose-dependent insulinotropic polypeptide, seems to present greater weight loss and glucose regulation compared existing treatments. Further clinical trials are needed to fully determine its sec